News

Vanda CEO expressed disappointment after FDA fails to approve jet lag disorder treatment due to unclear clinical significance.

The new device will treat patients who are not suited for other commonly used treatment options for advanced heart failure.

Children and adolescents have considerably fewer control therapy options for T2D. The GLP-1 agonist could be the first of its class for pediatric indication.

In a population-based cohort study, investigators discover how allergy immunotherapy helps allergic rhinitis from progressing to asthma.

What criteria should physicians follow to properly diagnose insomnia and its many comorbid conditions in older patients?

The association of depression symptoms with cognition and cortical amyloid measurements could lead to better therapies to prevent Alzheimer disease.

While many often turn to vitamins and nutritional supplements for nutrients their diet lacks, some argue this is not enough to make up for the missing nutrients.

Despite potentially playing a key role in the lives of patients, little is known about the true impact of gut microbiota on metabolic health. Hana Kahleova, MD, PhD, discusses the reality of our understanding in a recent interview.

The TAVR treatment was associated with a 46% reduction in one-year event risk among patients at low risk of open heart surgery.

After a 12-week study, investigators find a whole food diet, coupled with partial enteral nutrition, helps children with mild to moderate Crohn’s disease.

The once-daily capsule therapy is the first drug indicated for the rare disease since ruxolitinib in 2011.

The current vaccine strategy is effective, but lacks a streamlined approach.

While results of COMPASS proved the efficacy of combination rivaroxban-plus-aspirin, it may not be the best treatment for every patient suffering from coronary or peripheral artery disease.

A team of investigators review global HCV infection rates in an attempt to quantify HCV-associated cardiovascular disease.

Kala Pharmaceuticals will continue with an ongoing phase 3 trial assessing the solution, and could resubmit its NDA in 2020.

The approval marks the first ever treatment for patients with narcolepsy that is not scheduled as a controlled substance by the DEA.

A new study looks at the links between ADHD and bipolar disorder in children and adolescents.

The dynamic between a primary care doctor and a patient is the pathway to constructive and beneficial communication on fertility options.

After showing a significant impact on reduction of cardiovascular events, a slew of subgroup analyses were performed examining use of icosapent ethyl using data derived from REDUCE-IT.

A team of 6 hospital officials hope a comprehensive review of the 4 major hospital rating systems will yield a more uniform and reliable review process.

The August 14 approval marks the second drug approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.

The investigative monoclonal antibody from Regeneron shows significant benefit for patients with the rare, severe homozygous familial hypercholesterolemia.

In a new cohort study, investigators examine the link between blood pressure and cognitive decline.

A look into the reasoning behind the vaccine recommendations set by the CDC's Advisory Committee on Immunization Practice.

Trial investigator Deepak Bhatt, MD, MPH, discusses how use of rivaroxaban in a clinical setting has changed as a result of the COMPASS trial.

The first longitudinal study to assess air pollution and emphysema progression provides novel long-term findings.

The new FDA approval allows physicians to administer EYLEA in a prefilled syringe to treat retinal conditions with fewer preparation steps than vials.

Investigators find that ADHD drug MPH impacts the brain differently depending on age.